

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NALOX-1 PHARMACEUTICALS, LLC,

Petitioner,

v.

ADAPT PHARMA LIMITED,
OPIANT PHARMACEUTICALS, INC.,

Patent Owners

IPR2019-00699
U.S. Patent No. 9,775,838

DECLARATION OF MAUREEN DONOVAN, Ph.D.

*Inter Partes Review of U.S. Patent No. 9,775,838
Declaration of Maureen Donovan, Ph.D. (Nalox1002)*

TABLE OF CONTENTS

I.	OVERVIEW	1
II.	MY BACKGROUND AND QUALIFICATIONS	10
III.	LEGAL STANDARDS	13
	A. Person of ordinary skill in the art.....	13
	B. Claim construction	15
	C. Anticipation and obviousness.....	16
	D. Written description and priority	18
IV.	THE '838 PATENT AND ITS CLAIMS	19
	A. Background of the prior art relevant to the '838 patent.....	20
	1. Opioid overdose	20
	2. Prior intranasal formulations of naloxone	22
	3. Development of a new intranasal naloxone formulation.....	24
	(a) Physical and chemical properties of naloxone	24
	(b) Stability of the formulation.....	27
	(c) Nasal physiology	30
	(d) Drug exposure attributes for an improved intranasal formulation of naloxone.....	31
	(e) Choice of pharmaceutical excipients to achieve the desired exposure and stability attributes.....	33
	(f) Choice of delivery device	50
	(g) The properties of the nasal spray delivered by the spray device	51
	B. Independent claims 1 and 41	58

*Inter Partes Review of U.S. Patent No. 9,775,838
Declaration of Maureen Donovan, Ph.D. (Nalox1002)*

C.	Dependent claims 2–40 and 42–46	60
D.	The '838 patent lacks priority to U.S. Provisional Application No. 61/953,379.....	65
E.	Orange Book listing of the '838 patent.....	67
V.	CLAIM CONSTRUCTION	68
1.	“pre-primed”	69
2.	“delivery time”.....	69
VI.	PUBLIC ACCESSIBILITY OF THE PRIOR ART.....	69
A.	A Formulator POSA exercising reasonable diligence would have located Zomig Review.....	70
VII.	BASIS OF MY ANALYSIS WITH RESPECT TO OBVIOUSNESS.....	71
A.	A Formulator POSA reading Wyse in view of HPE would have had a reason and the know-how to arrive at the subject matter of claims 1–4, 18–23, 30–34, 36, and 39–40.....	71
1.	Claim 1	72
(a)	Preamble: “A method of treating opioid overdose, the method comprising:”	72
(b)	1.1: “delivering a 25-200 µL spray of a pharmaceutical solution”	73
(c)	1.2: “from a pre-primed device into a nostril of a patient, wherein the device is adapted for nasal delivery,”	75
(d)	1.3: “wherein the spray delivers between about 4 mg and about 10 mg naloxone,”	78
(e)	1.4: “an isotonicity agent,”	80
(f)	1.5: “and between about 0.005% and about 0.015% (w/v) of benzalkonium chloride,”.....	81

*Inter Partes Review of U.S. Patent No. 9,775,838
Declaration of Maureen Donovan, Ph.D. (Nalox1002)*

2.	Claim 2	84
3.	Claim 3	85
	(a) “the spray delivers about 100 µL of the pharmaceutical solution comprising”	86
	(b) “about 4% (w/v) naloxone hydrochloride;”	86
	(c) “about 0.74% (w/v) sodium chloride”	88
	(d) “about 0.01% (w/v) benzalkonium chloride”	92
	(e) “about 0.1% (w/v) disodium edetate.”	94
4.	Claim 4	96
5.	Claim 18	98
6.	Claim 19	99
7.	Claim 20	101
8.	Claim 21	101
9.	Claims 22–23	103
10.	Claim 30	106
11.	Claim 31	107
12.	Claim 32	108
	(a) “the pharmaceutical solution further comprises between about 0.1% and about 0.5% (w/v) of a stabilizing agent”	108
	(b) “and an amount of an acid sufficient to achieve a pH between about 3.5 and about 5.5.”	110
13.	Claim 33	111
	(a) “the isotonicity agent is sodium chloride;”	111
	(b) “the stabilizing agent is disodium edetate;”	112

***Inter Partes Review of U.S. Patent No. 9,775,838
Declaration of Maureen Donovan, Ph.D. (Nalox1002)***

(c)	“and the acid is hydrochloric acid.”	112
14.	Claim 34	112
15.	Claim 36	113
16.	Claims 39–40	117
B.	A Formulator POSA reading Wyse in view of HPE and Wang would have had a reason and the know-how to arrive at the subject matter of claims 5–12.....	120
1.	Claims 5–9	120
2.	Claims 10–12	124
C.	A Formulator POSA reading Wyse in view of HPE and the ’291 patent would have had a reason and the know-how to arrive at the subject matter of claims 13–17 and 41.....	127
1.	Claims 13–17	127
2.	Claim 41	131
(a)	“wherein the patient is in a lying, supine, or recovery position.”.....	133
(b)	“the patient experiences a geometric mean naloxone C _{max} not less than about 3 ng/mL following a single spray.”	136
D.	A Formulator POSA reading Wyse in view of HPE and Djupesland would have had a reason and the know-how to arrive at the subject matter of claims 24, 35, and 37.....	137
1.	Claim 24	137
2.	Claim 35	140
3.	Claim 37	143
E.	A Formulator POSA reading Wyse in view of HPE, Djupesland, and Zomig Review would have had a reason and the know-how to arrive at the subject matter of claim 38.....	145

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.